Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 1,652 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia Spectrum and Other Psychotic Disorders Clear all
Recruiting Phase 4 Interventional

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

NCT07105111
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Interventions
Valbenazine
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
19
States / cities
Bryant, Arkansas • Chino, California • Fresno, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 17, 2026, 10:34 AM EDT
Completed Phase 1Phase 2 Interventional

A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia

NCT02205099
View directory record Official record
Conditions
Schizophrenia
Interventions
SKL15508, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced Oct 17, 2026, 10:34 AM EDT
Completed Not applicable Interventional

Assertive Community Treatment With CBT and SST for Schizophrenia

NCT02254733
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive Behavioral Social Skills Training (CBSST), Assertive Community Treatment (ACT)
Behavioral · Other
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Oct 17, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Metabolic Signatures and Biomarkers in Schizophrenia

NCT00466310
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole, Risperidone, Healthy volunteers
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 60 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Butner, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 17, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation

NCT01646840
View directory record Official record
Conditions
Healthy
Interventions
PF-04958242 capsule, PF-04958242 oral solution
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 17, 2026, 10:34 AM EDT
Recruiting Phase 2 Interventional

Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia

NCT05778591
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Buprenorphine 0.15 MG [Belbuca]
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 17, 2026, 10:34 AM EDT
Withdrawn Not applicable Interventional

Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia

NCT02661347
View directory record Official record
Conditions
Schizophrenia, Schizophreniform, Schizoaffective Disorder, Psychosis Not Otherwise Specified (NOS)
Interventions
Risperidone, tDCS
Drug · Device
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 17, 2026, 10:34 AM EDT
Completed Not applicable Interventional Results available

Decision Support for Smoking Cessation in Young Adults With Severe Mental Illness

NCT01779440
View directory record Official record
Conditions
Mental Illness, Tobacco Smoking, Psychotic Disorders
Interventions
Electronic Decision Support System
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 30 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Manchester, New Hampshire • Nashua, New Hampshire • Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 17, 2026, 10:34 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis

NCT00591318
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizoaffective Disorder
Interventions
ceftriaxone, Normal Saline
Drug
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 17, 2026, 10:34 AM EDT
Terminated Phase 4 Interventional Results available

Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia

NCT01929889
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Iloperidone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2015 · Synced Oct 17, 2026, 10:34 AM EDT
Completed Not applicable Interventional

Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness

NCT02594696
View directory record Official record
Conditions
Major Depression, Schizophrenia, Bipolar Disorder, Lung Cancer, Breast Cancer, Head and Neck Cancer, GI Cancer, Cancer
Interventions
Proactive Psychiatry Consultation (PPC)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 17, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine

NCT00401973
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorders
Interventions
olanzapine, amantadine, metformin, zonisamide, Wellness education
Drug · Behavioral
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
National City, California • Canton, Ohio • Johnson City, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2009 · Synced Oct 17, 2026, 10:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Biomarkers in First Episode Schizophrenia

NCT02033382
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Depressed Type
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 40 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 17, 2026, 10:34 AM EDT
Terminated Phase 1 Interventional

Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia

NCT02968121
View directory record Official record
Conditions
Schizophrenia
Interventions
Brexpiprazole, OPDC-34712
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Garden Grove, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 17, 2026, 10:34 AM EDT
Terminated Not applicable Interventional Results available

Metformin for Weight Loss in Schizophrenia

NCT01177709
View directory record Official record
Conditions
Schizophrenia, Obesity
Interventions
Metformin
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Oct 17, 2026, 10:34 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Social Isolation and Aging in Schizophrenia

NCT07419321
View directory record Official record
Conditions
Schizophrenia and Related Disorders
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
40 Years to 70 Years
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 17, 2026, 10:34 AM EDT
Completed Not applicable Interventional

Mobile Enhancement of Motivation in Schizophrenia

NCT03059771
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Psychosis
Interventions
Mobile Enhancement of Motivation (MEMS), Control
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Oct 17, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

Pediatric Open-Label Extension Study

NCT01914393
View directory record Official record
Conditions
Schizophrenia, Autism, Bipolar Depression
Interventions
Lurasidone 20, 40, 60, 80 mg, flexibly dosed
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
35
States / cities
Dothan, Alabama • Downey, California • San Francisco, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Oct 17, 2026, 10:34 AM EDT
Completed No phase listed Observational

FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey

NCT00683891
View directory record Official record
Conditions
Weight Gain, Sialorrhea
Interventions
FazaClo (clozapine, USP) ODT
Drug
Lead sponsor
Azur Pharma, Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Costa Mesa, California • Gastonia, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 19, 2008 · Synced Oct 17, 2026, 10:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Randomized Controlled Trial of a Gluten Free Diet In Patients With Schizophrenia Who Are Gliadin-Positive

NCT01927276
View directory record Official record
Conditions
Schizophrenia
Interventions
Gluten Free Flour, Wheat Flour
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 17, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia

NCT00549718
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
21
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Oct 17, 2026, 10:34 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

NCT05443724
View directory record Official record
Conditions
Schizophrenia
Interventions
Emraclidine 30 mg
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
62
States / cities
Phoenix, Arizona • Bryant, Arkansas • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 17, 2026, 10:34 AM EDT
Completed Phase 1 Interventional

Bio-equivalence Study Between SAPHRIS and Asenapine

NCT01948024
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
SAPHRIS, Asenapine
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
7
States / cities
Little Rock, Arkansas • Costa Mesa, California • Garden Grove, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 17, 2026, 10:34 AM EDT
Completed Phase 3 Interventional

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

NCT01714661
View directory record Official record
Conditions
Schizophrenia, Impaired Cognition
Interventions
EVP-6124, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
38
States / cities
Tucson, Arizona • Anaheim, California • Bellflower, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 17, 2026, 10:34 AM EDT